Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials.

Calculation data download：DC198N0158.tmb